SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
130 hedge funds and large institutions have $47.7M invested in SANGAMO THERAPEUTICS INC in 2023 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 23 closing their positions.
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
3% less funds holding
Funds holding: 134 → 130 (-4)
8.15% less ownership
Funds ownership: 57.7% → 49.55% (-8.1%)
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
22% less capital invested
Capital invested by funds: $61.3M → $47.7M (-$13.7M)
38% less call options, than puts
Call options by funds: $45K | Put options by funds: $72K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$1M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$840K |
| 3 |
Two Sigma Investments
New York
|
+$589K |
| 4 |
Two Sigma Advisers
New York
|
+$573K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$554K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$3.94M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$2.58M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.22M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.52M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.13M |
SGMO Hedge Fund Activity: Q4 2023 in Review
130 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2023, worth a combined $47.7M — down 22% from $61.3M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SGMO and 19 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 42 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $1M. The largest seller was Rokos Capital Management (UK), exiting entirely with an estimated $3.94M sold.
- 130 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2023, down from 134 in Q3 2023.
- Funds reported $47.7M of SANGAMO THERAPEUTICS INC stock for Q4 2023, down 22% quarter-over-quarter.
- 19 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2023 and 23 closed out, a net change of -4 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2023 was D.E. Shaw & Co, an estimated $1M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2023 was Rokos Capital Management (UK), an estimated $3.94M sold.
Based on aggregated 13F filings for Q4 2023.